Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial

OBJECTIVE: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs. METHODS: Women with hormone receptor-positive early breast can...

Full description

Saved in:
Bibliographic Details
Published in:Menopause
Main Authors: Hirschberg, Angelica Lindén, Sánchez-Rovira, Pedro, Presa-Lorite, Jesús, Campos-Delgado, Miriam, Gil-Gil, Miguel, Lidbrink, Elisabet, Suárez-Almarza, Javier, Nieto-Magro, Concepción
Format: Artigo
Language:Inglês
Published: Lippincott-Raven Publishers 2020
Subjects:
Original Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188038/
https://ncbi.nlm.nih.gov/pubmed/32049923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001497
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items